February 27, 2020
Bottoms are not seeing breadth indicators stabilizing and sentiment resides inside the soul of the machines as electronic trading is totally agnostic
Q4 and FY19 results: Intellia Therapeutics (NTLA) and Sage Therapeutics (SAGE)
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.
February 26, 2020
When an upheaval strikes, it is vital how communication is a component of risk mitigation and how change is needed to propel a corporation back to a reality-based scenario.
For a public entity to attract investors, it must convey its financial and organizational “representation” in a clear, interconnected/unified and trustworthy method.
February 27, 2020
A dynamic in play, a dislocation that doesn’t let investors hide anywhere but, are we truly in correction territory after today’s freefall?
Time to look for opportunity in these bottoms – look at cash positions and tread lightly until the full extent of the outbreak is known!
I make a commitment to provide need-to-know “facts in evidence” as equity’s volatility is one tactical signal for stocks.
February 18, 2020
A scorecard of earnings of 35 covered companies The current LPS (loss per share) or net income, cash positions i.e. "runways" - is a reflection of this universe's investing "status"
December 6, 2019
Dropping -$89.03 on Thursday and is up +$4.23 or +7.91% on Friday One day removed after shares of SAGE falling -59.7%, the stock is "bouncing" higher in trading after hitting 52-week lows on Thursday.
November 3, 2019
Fate Therapeutics (FATE), Vericel (VCEL), Regenxbio (RGNX) and Ultragenyx (RARE) on 11/5; AxoGen (AXGN), Athersys (ATHX), Ionis Pharmaceuticals (IONS), Sangamo Therapeutics (SGMO), Voyager Therapeutics (VYGR), Bellicum Pharmaceuticals (BLCM) and Caladrius Biosciences (CLBS) on 11/6; Adverum Biotechnologies (ADVM), Audentes Therapeutics (BOLD) and Cellectis (CLLS) and Stemline Therapeutics (STML) on 11/7 …. and Biostage (BSTG) , BioLife Solutions (BLFS), and Applied Genetic Technologies (AGTC) on 10/12
The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.